Jul 27, 2025, 16:48

Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)

The National Cancer Institute (NCI) invites R33 grant applications to support advanced development and rigorous validation of novel molecular or cellular analysis technologies that offer transformative capabilities for cancer research, including basic biology, early detection, diagnostics, treatment, and disparities research .

Eligibility Criteria:

U.S. and foreign organizations of any type, including higher education institutions, nonprofit and for-profit entities (small businesses and others), local/state/federal governments, and tribal organizations.
Foreign components of U.S. organizations and standalone foreign organizations are eligible.
Applicant institutions must have required registrations (SAM, UEI, NCAGE if applicable, eRA Commons, Grants.gov) completed prior to submission .
PD(s)/PI(s) must have eRA Commons accounts; organizational Signing Officials require separate accounts.
Multi-PD/PI applications are allowed under NIH’s MPI policy.

Funding Details:

Estimated 10 awards in FY2026, total budget ~4.3 M USD.
Up to 300,000 USD direct costs per year; project period up to 3 years.
No clinical trials allowed.
Funds may cover technology development, validation experiments, performance measure assessments, and related personnel, supplies, and core costs; must follow NIH cost principles .

Deadline:

Letter of Intent: 30 days before application due date
Application Due Dates: April 4, 2025 and October 3, 2025 (by 5:00 PM local applicant time)
Scientific Merit Review: July 2025 (first cycle), February 2026 (second cycle)
Earliest Start Dates: December 2025 and July 2026 respectively .

Where to Go for Further Information:

Prepare and submit applications via NIH ASSIST, Grants.gov Workspace, or institutional S2S.
Funding Opportunity Number: RFA-CA-25-002.
Contact Kelly Crotty, Ph.D. (NCI) at [email protected] for scientific inquiries; [email protected] for application guidance; Grants.gov Support at [email protected] for system help.

cancer Cancer research cellular analysis Diagnostics early detection exploratory developmental grant Health Disparities IMAT program molecular analysis NCI NIH OncoDaily Oncology R33 technology development treatment validation

Ruben Mesa is Starting a New Position as President of Cancer National Service Line at Advocate Health

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Dana Dornsife: After 19 Years, Lazarex Cancer Foundation Is Shuttering Because of Lack of Funding

Matt Sherer: ASCO Supports Permanent Medicare Telehealth

New FDA PreCheck Program to Boost U.S. Drug Manufacturing